You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

787 Results
The Ontario Cancer Registry SEER*Stat Package contains de-identified Ontario cancer data files derived from the Ontario Cancer Registry, the SEER*...
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab,
gemcitabine,
oxaliplatin,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2026
Drug
Quick Link(s):
Drug Monograph, Patient Info Sheet
Oct 2023
Guidelines and Advice
Status: In-Review
ID: GL 5-3ORG
Version: 2
Dec 1969
Guidelines and Advice
Status: Archived
ID: 17-4
Version: 2
Nov 2016
Drug
Other Name(s): Zoladex® , Zoladex® LA
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Mar 2026
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    goserelin
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
goserelin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Mar 2026

Pages